These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8814313)

  • 1. Evaluation of human cytokine production and effects of pharmacological agents in a heterologous system in vivo.
    Griswold DE; Hillegass LM; O'Leary-Bartus J; Lee JC; Laydon JT; Torphy TJ
    J Immunol Methods; 1996 Sep; 195(1-2):1-5. PubMed ID: 8814313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
    Pettipher ER; Labasi JM; Salter ED; Stam EJ; Cheng JB; Griffiths RJ
    Br J Pharmacol; 1996 Apr; 117(7):1530-4. PubMed ID: 8730750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
    Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
    Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
    Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
    Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A.
    Hartman DA; Ochalski SJ; Carlson RP
    Inflamm Res; 1995 Jul; 44(7):269-74. PubMed ID: 8564522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
    Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S
    Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibitory effect of rolipram on TNF-alpha production in mouse blood ex vivo is dependent upon the release of corticosterone and adrenaline.
    Pettipher ER; Eskra JD; Labasi JM
    Cytokine; 1997 Aug; 9(8):582-6. PubMed ID: 9245486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.
    Haddad EB; Birrell M; McCluskie K; Ling A; Webber SE; Foster ML; Belvisi MG
    Br J Pharmacol; 2001 Apr; 132(8):1715-24. PubMed ID: 11309243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness.
    Faas MM; Moes H; Fijen JW; Muller Kobold AC; Tulleken JE; Zijlstra JG
    Clin Exp Immunol; 2002 Feb; 127(2):337-43. PubMed ID: 11876759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
    Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
    AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.
    Eigler A; Siegmund B; Emmerich U; Baumann KH; Hartmann G; Endres S
    J Leukoc Biol; 1998 Jan; 63(1):101-7. PubMed ID: 9469479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
    Semmler J; Wachtel H; Endres S
    Int J Immunopharmacol; 1993 Apr; 15(3):409-13. PubMed ID: 8505151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
    J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of phosphodiesterase inhibitors on cytokine production by microglia.
    Yoshikawa M; Suzumura A; Tamaru T; Takayanagi T; Sawada M
    Mult Scler; 1999 Apr; 5(2):126-33. PubMed ID: 10335522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.